Taxanes in the elderly patient with metastatic breast cancer

References

• HowladerNNooneAMKrapchoMSEER Cancer Statistics Review, 1975–2011Bethesda, MDNational Cancer Institute2014
   Google Scholar
• SmithBDJiangJMcLaughlinSSImprovement in breast cancer outcomes over time: are older women missing out?J Clin Oncol201129354647465322067407
   PubMed Web of Science ®Google Scholar
• BouchardyCRapitiEFiorettaGUndertreatment strongly decreases prognosis of breast cancer in elderly womenJ Clin Oncol200321193580358712913099
   PubMed Web of Science ®Google Scholar
• BiganzoliLWildiersHOakmanCManagement of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)Lancet Oncol2012134e148e16022469125
   PubMed Web of Science ®Google Scholar
• HurriaALichtmanSMClinical pharmacology of cancer therapies in older adultsBr J Cancer200898351752218256586
   PubMed Web of Science ®Google Scholar
• VestalREAging and pharmacologyCancer1997807130213109317183
   PubMed Web of Science ®Google Scholar
• Fehrman-EkholmISkeppholmLRenal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearanceScand J Urol Nephrol2004381737715204431
   PubMed Web of Science ®Google Scholar
• BorkowskiJMDuerrMDonehowerRCRelation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic dataCancer Chemother Pharmacol19943364934968137460
   PubMed Web of Science ®Google Scholar
• NixonAJNeubergDHayesDFRelationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancerJ Clin Oncol19941258888948164038
   PubMed Web of Science ®Google Scholar
• DiabSGElledgeRMClarkGMTumor characteristics and clinical outcome of elderly women with breast cancerJ Natl Cancer Inst200092755055610749910
   PubMed Web of Science ®Google Scholar
• RingASestakIBaumMInfluence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the arimidex, tamoxifen alone or in combination trialJ Clin Oncol201129324266427221990403
   PubMed Web of Science ®Google Scholar
• HurriaAEmbracing the complexity of comorbidityJ Clin Oncol201129324217421821990401
   PubMed Web of Science ®Google Scholar
• Von HoffDDRozencweigMLayardMSlavikMMuggiaFMDaunomycin-induced cardiotoxicity in children and adults. A review of 110 casesAm J Med1977622200208835599
   PubMed Web of Science ®Google Scholar
• Von HoffDDLayardMWBasaPRisk factors for doxorubicin-induced congestive heart failureAnn Intern Med1979915710717496103
   PubMed Web of Science ®Google Scholar
• OnitiloAAEngelJMStankowskiRVCardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factorsTher Adv Drug Saf20145415416625083270
   PubMedGoogle Scholar
• DelafuenteJCUnderstanding and preventing drug interactions in elderly patientsCrit Rev Oncol Hematol200348213314314607376
   PubMed Web of Science ®Google Scholar
• ChristmanKMussHBCaseLDStanleyVChemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment]JAMA1992268157621608114
   PubMed Web of Science ®Google Scholar
• The National Comprehensive Cancer NetworkNational Comprehensive Cancer Network Clinical Practice Guidelines in OncologyBreast Cancer. Version 220152015
   Google Scholar
• NahtaRHungMCEstevaFJThe HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cellsCancer Res20046472343234615059883
   PubMed Web of Science ®Google Scholar
• Xeloda® (capecitabine) [package insert]South San Francisco, CAGenentech2011
   Google Scholar
• Taxotere® (docetaxel) Injection Concentrate [package insert]Bridgewater, NJSanofiaventis US LLC2010
   Google Scholar
• Adriamycin® (doxorubicin HCl) for Injection, USP [package insert]Bedford, OHBedford Laboratories2012
   Google Scholar
• Taxol^® (paclitaxel) [package insert]PrincetonNJBristol-Myers Squibb Company2011
   Google Scholar
• Abraxane® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) [package insert]Summit, NJCelegene Corporation2014
   Google Scholar
• SchiffPBFantJHorwitzSBPromotion of microtubule assembly in vitro by taxolNature19792775698665667423966
   PubMed Web of Science ®Google Scholar
• SchiffPBHorwitzSBTaxol stabilizes microtubules in mouse fibroblast cellsProc Natl Acad Sci U S A1980773156115656103535
   PubMed Web of Science ®Google Scholar
• WaniMCTaylorHLWallMECoggonPMcPhailATPlant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from taxus brevifoliaJ Am Chem Soc1971939232523275553076
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJExtending survival with chemotherapy in metastatic breast cancerOncologist200510Suppl 3202916368868
   PubMed Web of Science ®Google Scholar
• ten TijeAJVerweijJLoosWJSparreboomAPharmacological effects of formulation vehicles: implications for cancer chemotherapyClin Pharmacokinet200342766568512844327
   PubMed Web of Science ®Google Scholar
• GradisharWJTjulandinSDavidsonNPhase III trial of nano-particle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerJ Clin Oncol200523317794780316172456
   PubMed Web of Science ®Google Scholar
• SmorenburgCHten TijeAJVerweijJAltered clearance of unbound paclitaxel in elderly patients with metastatic breast cancerEur J Cancer200339219620212509952
   PubMed Web of Science ®Google Scholar
• van ZuylenLVerweijJSparreboomARole of formulation vehicles in taxane pharmacologyInvest New Drugs200119212514111392447
   PubMed Web of Science ®Google Scholar
• GelderblomHVerweijJBrouwerEDisposition of [G-(3)H] paclitaxel and cremophor EL in a patient with severely impaired renal functionDrug Metab Dispos199927111300130510534315
   PubMed Web of Science ®Google Scholar
• PandayVRHuizingMTWillemsePHHepatic metabolism of paclitaxel and its impact in patients with altered hepatic functionSemin Oncol1997244 Suppl 11S11-34S11-389314297
   PubMed Web of Science ®Google Scholar
• GianniLKearnsCMGianiANonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humansJ Clin Oncol19951311801907799018
   PubMed Web of Science ®Google Scholar
• LichtmanSMHurriaACirrincioneCTPaclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840Ann Oncol201223363263821693770
   PubMed Web of Science ®Google Scholar
• BeuselinckBWildiersHWynendaeleWDirixLKainsJPParidaensRWeekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical OncologyCrit Rev Oncol Hematol2010751707719651523
   PubMed Web of Science ®Google Scholar
• ten TijeAJSmorenburgCHSeynaeveCWeekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trialEur J Cancer200440335235714746852
   PubMed Web of Science ®Google Scholar
• Del MastroLPerroneFRepettoLWeekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)Ann Oncol200516225325815668279
   PubMed Web of Science ®Google Scholar
• SmorenburgCHten TijeAJReply to “weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)” by L. del Mastro et al. (Ann Oncol 2005;16:253–258)Ann Oncol200516121979 author reply 1979–198016030026
   PubMed Web of Science ®Google Scholar
• ten TijeAJVerweijJCarducciMAProspective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderlyJ Clin Oncol20052361070107715718305
   PubMed Web of Science ®Google Scholar
• PivotXSchneeweissAVermaSEfficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADOEur J Cancer201147162387239521757334
   PubMed Web of Science ®Google Scholar
• HainsworthJDBurrisHA3rdYardleyDAWeekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trialJ Clin Oncol200119153500350511481356
   PubMed Web of Science ®Google Scholar
• D’hondtRParidaensRWildiersHSafety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II studyAnticancer Drugs200415434134615057137
   PubMed Web of Science ®Google Scholar
• MaisanoRMareMCaristiNA modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety studyJ Chemother200517224224615920913
   PubMed Web of Science ®Google Scholar
• LorenzoIConstenlaMPalaciosPDocetaxel as single-agent treatment in elderly patients with advanced breast cancerClin Drug Investig2005254249256
   PubMed Web of Science ®Google Scholar
• MassacesiCMarcucciFBoccettiTLow dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancerJ Exp Clin Cancer Res2005241434815943030
   PubMed Web of Science ®Google Scholar
• GardnerERDahutWLScriptureCDRandomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxelClin Cancer Res200814134200420518594000
   PubMed Web of Science ®Google Scholar
• HurriaABlanchardMSSynoldTWAge-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional ageOncologist2015201374425492923
   PubMed Web of Science ®Google Scholar
• AaproMTjulandinSBharPGradisharWWeekly nab-paclitaxel is safe and effective in >/=65 years old patients with metastatic breast cancer: a post-hoc analysisBreast201120546847421843943
   PubMed Web of Science ®Google Scholar
• GradisharWJKrasnojonDCheporovSSignificantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancerJ Clin Oncol200927223611361919470941
   PubMed Web of Science ®Google Scholar
• PallisAGFortpiedCWeddingUEORTC elderly task force position paper: approach to the older cancer patientEur J Cancer20104691502151320227872
   PubMed Web of Science ®Google Scholar
• PallisAGWeddingULacombeDSoubeyranPWildiersHQuestionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know?Eur J Cancer20104661019102520138506
   PubMed Web of Science ®Google Scholar
• PACE participants; AudisioRAPopeDShall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective studyCrit Rev Oncol Hematol200865215616318082416
   PubMed Web of Science ®Google Scholar
• HurriaACirrincioneCTMussHBImplementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401J Clin Oncol201129101290129621357782
   PubMed Web of Science ®Google Scholar
• SoubeyranPBelleraCGoyardJValidation of the G8 screening tool in geriatric oncology: the ONCODAGE projectJ Clin Oncol (Meeting Abstracts)20112915 Suppl Abstract 9001
   Web of Science ®Google Scholar
• SinglaAKGargAAggarwalDPaclitaxel and its formulationsInt J Pharm20022351–217919211879753
   PubMed Web of Science ®Google Scholar
• LuoCWangYChenQAdvances of paclitaxel formulations based on nanosystem delivery technologyMini Rev Med Chem201212543444422303950
   PubMed Web of Science ®Google Scholar
• EngelsFKMathotRAVerweijJAlternative drug formulations of docetaxel: a reviewAnticancer Drugs20071829510317159596
   PubMed Web of Science ®Google Scholar
• SehlMSawhneyRNaeimAPhysiologic aspects of aging: impact on cancer management and decision making, part IICancer J200511646147316393480
   PubMedGoogle Scholar
• BalducciLMowryKPharmacology and organ toxicity of chemotherapy in older patientsOncology (Williston Park)199262 Suppl62681532739
   PubMedGoogle Scholar
• DavisMPSrivastavaMDemographics, assessment and management of pain in the elderlyDrugs Aging2003201235712513114
   PubMed Web of Science ®Google Scholar
• YancikRWesleyMNRiesLAHavlikRJEdwardsBKYatesJWEffect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and olderJAMA2001285788589211180731
   PubMed Web of Science ®Google Scholar
• DaousiCMacFarlaneIAWoodwardANurmikkoTJBundredPEBenbowSJChronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetesDiabet Med200421997698215317601
   PubMed Web of Science ®Google Scholar
• HickishTAstrasGThomasPGlucose intolerance during adjuvant chemotherapy for breast cancerJ Natl Cancer Inst2009101753719318627
   PubMedGoogle Scholar